OTC · CIK 0001864531
VSEE VSEE HEALTH, INC.
Insider trading from SEC Form 4. Last filing Jun 2, 2026.
VSEE HEALTH, INC. (VSEE) has 20 SEC Form 4 filings on file from 8 insiders, the latest filed on Jun 2, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Signals
Open-market buys and sells at VSEE HEALTH, INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The newest 50 of 58 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 31, 2026 | Milton Chen Co-Chief Executive Officer | JOther Common Stock, par value $0.0001 per share | -2,870,069 | $0.00 | $0 | 0 | Jun 2, 2026 |
| Mar 23, 2026 | Imoigele Aisiku Co-Chief Executive Officer | AGrant or award Common Stock, par value $0.0001 per share | +128,342 | $0.37 | $47k | 3,545,031 | Mar 24, 2026 |
| Mar 23, 2026 | Jerry Leonard Chief Financial Officer | AGrant or award Common Stock, par value $0.0001 per share | +66,845 | $0.37 | $25k | 710,938 | Mar 24, 2026 |
| Mar 23, 2026 | Imoigele Aisiku Co-Chief Executive Officer | AGrant or award Common Stock, par value $0.0001 per share | +78,689 | $0.61 | $48k | 3,416,689 | Mar 24, 2026 |
| Mar 23, 2026 | Jerry Leonard Chief Financial Officer | AGrant or award Common Stock, par value $0.0001 per share | +40,984 | $0.61 | $25k | 644,093 | Mar 24, 2026 |
| Mar 23, 2026 | Jerry Leonard Chief Financial Officer | AGrant or award Common Stock, par value $0.0001 per share | +21,552 | $1.16 | $25k | 603,109 | Mar 24, 2026 |
| Mar 23, 2026 | Imoigele Aisiku Co-Chief Executive Officer | AGrant or award Common Stock, par value $0.0001 per share | +41,379 | $1.16 | $48k | 3,338,000 | Mar 24, 2026 |
| Mar 23, 2026 | Jerry Leonard Chief Financial Officer | AGrant or award Common Stock, par value $0.0001 per share | +20,833 | $1.20 | $25k | 581,557 | Mar 24, 2026 |
| Mar 23, 2026 | Imoigele Aisiku Co-Chief Executive Officer | AGrant or award Common Stock, par value $0.0001 per share | +40,000 | $1.20 | $48k | 3,296,621 | Mar 24, 2026 |
| Mar 4, 2026 | Colin P. O'Sullivan director | AGrant or award Common Stock, par value $0.0001 per share | +40,107 | $0.37 | $15k | 108,731 | Mar 6, 2026 |
| Mar 4, 2026 | Scott Metzger director | AGrant or award Common Stock, par value $0.0001 per share | +40,107 | $0.37 | $15k | 117,356 | Mar 6, 2026 |
| Mar 4, 2026 | Cydonii V. Fairfax director | AGrant or award Common Stock, par value $0.0001 per share | +40,107 | $0.37 | $15k | 108,504 | Mar 5, 2026 |
| Mar 4, 2026 | Kevin Lowdermilk director | AGrant or award Common Stock, par value $0.0001 per share | +40,107 | $0.37 | $15k | 108,731 | Mar 5, 2026 |
| Mar 4, 2026 | David L. Wickersham director | AGrant or award Common Stock, par value $0.0001 per share | +40,107 | $0.37 | $15k | 1,187,671 | Mar 5, 2026 |
| Feb 23, 2026 | David L. Wickersham director | CConversion Common Stock, par value $0.0001 per shareindirect: See footnote | +759,916 | $0.32 | $243k | 1,147,564 | Feb 25, 2026 |
| Feb 23, 2026 | David L. Wickersham director | CConversion Common Stock, par value $0.0001 per shareindirect: See footnote | +105,251 | $0.65 | $68k | 387,648 | Feb 25, 2026 |
| Feb 23, 2026 | David L. Wickersham director | CConversion Convertible Promissory Notederivativeindirect: See footnote | - | $0.00 | - | 0 | Feb 25, 2026 |
| Feb 23, 2026 | David L. Wickersham director | CConversion Convertible Promissory Notederivativeindirect: See footnote | - | $0.00 | - | 0 | Feb 25, 2026 |
| Aug 15, 2025 | Imoigele Aisiku Co-Chief Executive Officer | JOther Common Stock, par value $0.0001 per share | -25,000 | $2.00 | $50k | 3,256,621 | Feb 19, 2026 |
| Aug 14, 2025 | David L. Wickersham director | JOther Common Stock, par value $0.0001 per share | +100,000 | $2.00 | $200k | 214,000 | Feb 19, 2026 |
| Aug 14, 2025 | Imoigele Aisiku Co-Chief Executive Officer | JOther Common Stock, par value $0.0001 per share | -100,000 | $2.00 | $200k | 3,281,621 | Feb 19, 2026 |
| Sep 19, 2025 | Colin P. O'Sullivan director | AGrant or award Common Stock, par value $0.0001 per share | +21,870 | $0.69 | $15k | 68,624 | Jan 16, 2026 |
| Sep 19, 2025 | David L. Wickersham director | AGrant or award Common Stock, par value $0.0001 per share | +21,870 | $0.69 | $15k | 282,397 | Jan 16, 2026 |
| Sep 19, 2025 | Kevin Lowdermilk director | AGrant or award Common Stock, par value $0.0001 per share | +21,870 | $0.69 | $15k | 68,624 | Jan 16, 2026 |
| Sep 19, 2025 | Scott Metzger director | AGrant or award Common Stock, par value $0.0001 per share | +21,870 | $0.69 | $15k | 77,249 | Jan 16, 2026 |
| Sep 19, 2025 | Cydonii V. Fairfax director | AGrant or award Common Stock, par value $0.0001 per share | +21,870 | $0.69 | $15k | 68,397 | Jan 16, 2026 |
| Sep 19, 2025 | Scott Metzger director | AGrant or award Common Stock, par value $0.0001 per share | +12,931 | $1.16 | $15k | 55,379 | Jan 16, 2026 |
| Sep 19, 2025 | David L. Wickersham director | AGrant or award Common Stock, par value $0.0001 per share | +12,931 | $1.16 | $15k | 260,527 | Jan 16, 2026 |
| Sep 19, 2025 | Colin P. O'Sullivan director | AGrant or award Common Stock, par value $0.0001 per share | +12,931 | $1.16 | $15k | 46,754 | Jan 16, 2026 |
| Sep 19, 2025 | Cydonii V. Fairfax director | AGrant or award Common Stock, par value $0.0001 per share | +12,931 | $1.16 | $15k | 46,527 | Jan 16, 2026 |
| Sep 19, 2025 | Kevin Lowdermilk director | AGrant or award Common Stock, par value $0.0001 per share | +12,931 | $1.16 | $15k | 46,754 | Jan 16, 2026 |
| Sep 19, 2025 | David L. Wickersham director | AGrant or award Common Stock, par value $0.0001 per share | +12,500 | $1.20 | $15k | 247,596 | Jan 16, 2026 |
| Sep 19, 2025 | Scott Metzger director | AGrant or award Common Stock, par value $0.0001 per share | +12,500 | $1.20 | $15k | 42,448 | Jan 16, 2026 |
| Sep 19, 2025 | Colin P. O'Sullivan director | AGrant or award Common Stock, par value $0.0001 per share | +12,500 | $1.20 | $15k | 33,823 | Jan 16, 2026 |
| Sep 19, 2025 | Cydonii V. Fairfax director | AGrant or award Common Stock, par value $0.0001 per share | +12,500 | $1.20 | $15k | 33,596 | Jan 16, 2026 |
| Sep 19, 2025 | Kevin Lowdermilk director | AGrant or award Common Stock, par value $0.0001 per share | +12,500 | $1.20 | $15k | 33,823 | Jan 16, 2026 |
| Sep 19, 2025 | David L. Wickersham director | AGrant or award Common Stock, par value $0.0001 per share | +11,029 | $1.36 | $15k | 235,096 | Jan 16, 2026 |
| Sep 19, 2025 | Scott Metzger director | AGrant or award Common Stock, par value $0.0001 per share | +11,029 | $1.36 | $15k | 29,948 | Jan 16, 2026 |
| Sep 19, 2025 | Colin P. O'Sullivan director | AGrant or award Common Stock, par value $0.0001 per share | +11,029 | $1.36 | $15k | 21,323 | Jan 16, 2026 |
| Sep 19, 2025 | Cydonii V. Fairfax director | AGrant or award Common Stock, par value $0.0001 per share | +11,029 | $1.36 | $15k | 21,096 | Jan 16, 2026 |
| Sep 19, 2025 | Kevin Lowdermilk director | AGrant or award Common Stock, par value $0.0001 per share | +11,029 | $1.36 | $15k | 21,323 | Jan 16, 2026 |
| Sep 19, 2025 | Scott Metzger director | AGrant or award Common Stock, par value $0.0001 per share | +10,067 | $1.49 | $15k | 18,919 | Jan 16, 2026 |
| Sep 19, 2025 | Colin P. O'Sullivan director | AGrant or award Common Stock, par value $0.0001 per share | +10,067 | $1.49 | $15k | 10,294 | Jan 16, 2026 |
| Sep 19, 2025 | David L. Wickersham director | AGrant or award Common Stock, par value $0.0001 per share | +10,067 | $1.49 | $15k | 224,067 | Jan 16, 2026 |
| Sep 19, 2025 | Cydonii V. Fairfax director | AGrant or award Common Stock, par value $0.0001 per share | +10,067 | $1.49 | $15k | 10,067 | Jan 16, 2026 |
| Sep 19, 2025 | Kevin Lowdermilk director | AGrant or award Common Stock, par value $0.0001 per share | +10,067 | $1.49 | $15k | 10,294 | Jan 16, 2026 |
| Sep 19, 2025 | Kevin Lowdermilk director | AGrant or award Common Stock, par value $0.0001 per share | +227 | $2.31 | $524 | 227 | Jan 16, 2026 |
| Sep 19, 2025 | Scott Metzger director | AGrant or award Common Stock, par value $0.0001 per share | +227 | $2.31 | $524 | 8,852 | Jan 16, 2026 |
| Sep 19, 2025 | Colin P. O'Sullivan director | AGrant or award Common Stock, par value $0.0001 per share | +227 | $2.31 | $524 | 227 | Jan 16, 2026 |
| Sep 19, 2025 | Jerry Leonard Chief Financial Officer | AGrant or award Common Stock, par value $0.0001 per share | +300,000 | $0.00 | $0 | 560,724 | Jan 7, 2026 |
50 of 58 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Imoigele AisikuCo-Chief Executive Officer
- Milton ChenCo-Chief Executive Officer
- Cydonii V. Fairfaxdirector
- Kevin Lowdermilkdirector
- Jerry LeonardChief Financial Officer
- Scott Metzgerdirector
- Colin P. O'Sullivandirector
- David L. Wickershamdirector
Questions about VSEE
Answered from the filings on this page, as of the latest one.
Are insiders buying VSEE?
No. In the last 90 days no insider at VSEE HEALTH, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade VSEE on the open market?
No open-market trade has been scored at VSEE HEALTH, INC.. The latest Form 4 on file was filed on Jun 2, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at VSEE HEALTH, INC.?
8 people have filed a Form 4 at VSEE HEALTH, INC., among them Imoigele Aisiku (Co-Chief Executive Officer), Milton Chen (Co-Chief Executive Officer), Cydonii V. Fairfax (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.